Bonimet 

Gemtide (Teriparatide 250 mcg Injection) is a prescription medication used to treat osteoporosis in postmenopausal women. It is a recombinant human parathyroid hormone that helps to stimulate bone formation and increase bone density.

Composition:

Each 0.5 mL injection of Gemtide contains 250 mcg of teriparatide, a fragment of human parathyroid hormone (1-34). The injectable solution is sterile and preservative-free.

Mechanism of Action:

Gemtide works by mimicking the action of endogenous parathyroid hormone, which helps to regulate calcium and phosphate levels in the body. By stimulating osteoblasts (bone-forming cells), Gemtide increases bone formation and density, reducing the risk of osteoporotic fractures.

Dosage:

The recommended dosage of Gemtide is 20 mcg administered subcutaneously once daily. The injection should be given in the morning, at least 30 minutes before breakfast.

Uses:

Gemtide is indicated for the treatment of osteoporosis in postmenopausal women with a history of vertebral fractures or other risk factors for osteoporosis.

Side Effects:

Common side effects of Gemtide include:

• Nausea
• Headache
• Dizziness
• Fatigue
• Muscle weakness
• Joint pain

Rare but serious side effects include:

• Increased risk of osteosarcoma (a type of bone cancer)
• Hypercalcemia (elevated calcium levels)

Recommendation:

Gemtide should be used under the guidance of a healthcare professional. Patients should be monitored regularly for changes in bone density, calcium levels, and signs of hypercalcemia.

Important Note:

Gemtide is not recommended for use in:

• Patients with Paget’s disease or other conditions that increase bone turnover
• Patients with kidney disease or severe liver disease
• Patients with a history of kidney stones or other mineral disorders
• Pregnant or breastfeeding women

Additionally, patients with a history of osteosarcoma or other bone cancer should not use Gemtide.